

6 March 2026

### Transactions by Persons Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 4 March 2026, awards of the Company's ordinary shares of 0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP).

The AZDBP award was granted on 4 March 2023, following the deferral of a portion of each PDMR's annual bonus in respect of 2022 performance into Ordinary Shares, and vested on completion of the three-year holding period.

Following the reinvestment of dividends accrued during the deferral period of the AZDBP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below.

PDMR	Position	Ordinary Shares acquired
Pascal Soriot	Executive Director and Chief Executive Officer	14,967
Aradhana Sarin	Executive Director and Chief Financial Officer	4,863

For tax purposes, the fair market value of an Ordinary Share at vest of the AZDBP award was 14,932 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>					
a)	Name	Pascal Soriot				
<b>2</b>	<b>Reason for the notification</b>					
a)	Position/status	Chief Executive Officer				
b)	Initial notification /Amendment	Initial notification				
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name	AstraZeneca PLC				
b)	LEI	PY6ZZQWO2IZFZC3IOL08				
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument	Ordinary Shares of US 0.25 each in AstraZeneca PLC				
	Identification code	GB0009895292				
b)	Nature of the transaction	Acquisition of Ordinary Shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>14,967</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0	14,967
Price(s)	Volume(s)					
0	14,967					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				
e)	Date of the transaction	4 March 2026				
f)	Place of the transaction	Outside a trading venue				

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>					
a)	Name	Aradhana Sarin				
<b>2</b>	<b>Reason for the notification</b>					
a)	Position/status	Chief Financial Officer				
b)	Initial notification /Amendment	Initial notification				
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name	AstraZeneca PLC				
b)	LEI	PY6ZZQWO2IZFZC3IOL08				
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of US 0.25 each in AstraZeneca PLC  GB0009895292				
b)	Nature of the transaction	Acquisition of Ordinary Shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>4,863</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0	4,863
Price(s)	Volume(s)					
0	4,863					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				
e)	Date of the transaction	4 March 2026				
f)	Place of the transaction	Outside a trading venue				

### [AstraZeneca](#)

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit [astrazeneca.com](https://www.astrazeneca.com) and follow the Company on Social Media [@AstraZeneca](#).

### Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

**Matthew Bowden**  
Company Secretary  
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHUNVWRNRUORRR